TMDX
TransMedics Group, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$71.60
+1.16%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$70.50
From 52W high−52.40%
Volume653982.00
Market cap$2.48B
P/E (TTM)16.2x
P/S (TTM)3.7x
Div yield—
Key dataOct 19, 2026
Open
$70.50
From 52W high
−52.40%
Volume
653982.00
Market cap
$2.48B
ValuationView details →
P/E (Fwd)
34.3x
EV/EBITDA
22.1x
P/E (TTM)
16.2x
RSI (14)
34.3
MomentumView details →
1D Return
+1.16%
YTD Return
−40.75%
SummaryUpdated Jun 1, 2026
TransMedics Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company founded in 1998 and headquartered in Andover, Massachusetts. The company has transformed from a research-focused startup into a leading provider of organ preservation technology for transplant procedures. TransMedics went public in May 2019 and has since established itself as a key player in the organ transplantation market, operating primarily in the United States with expanding international presence. The company has experienced rapid growth, particularly following the launch of its National OCS Program (NOP) which provides comprehensive transplant logistics services.
Similar companies
Latest newsMore news →
TransMedics Group, Inc. appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective September 21, 2026.39d agoEmerald Investment Advisers LLC acquired a new stake of 30,456 shares in TransMedics Group, Inc. during the quarter, valued at approximately $2,023,000, as disclosed to the SEC.58d ago